Takeda says Phase 3 psoriasis data show zasocitinib outperforms BMS’ deucravacitinib

Takeda reported new Phase 3 plaque psoriasis data for oral TYK2 inhibitor zasocitinib presented at EADV Congress 2026, with earlier and stronger skin-clearance outcomes versus Bristol Myers Squibb’s deucravacitinib and responses holding over longer follow-up, plus faster itch and quality-of-life improvements; safety was consistent with no new signals flagged.